{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T08:02:14Z","timestamp":1780128134821,"version":"3.54.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Epidemiology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.canep.2025.102960","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T09:27:23Z","timestamp":1763371643000},"page":"102960","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Temporal trends in AML incidence and mortality, with a focus on AML-related deaths among patients with myelodysplastic syndromes in the United States, 1999\u20132023"],"prefix":"10.1016","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9260-2747","authenticated-orcid":false,"given":"Natalie A.","family":"Akoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert E.","family":"Orhin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8243-7228","authenticated-orcid":false,"given":"Denise Eke","family":"Chukwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Gyato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4960-6114","authenticated-orcid":false,"given":"Simon","family":"Egyin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0405-9419","authenticated-orcid":false,"given":"Maame Yaa","family":"Idun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwabena Owusu","family":"Aninkora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.canep.2025.102960_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-022-00765-8","article-title":"Management of patients with lower-risk myelodysplastic syndromes","volume":"12","author":"Brunner","year":"2022","journal-title":"Blood Cancer J."},{"issue":"6","key":"10.1016\/j.canep.2025.102960_bib2","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.blre.2005.01.004","article-title":"Myelodysplasic syndromes: a comprehensive review","volume":"19","author":"Catenacci","year":"2005","journal-title":"Blood Rev."},{"key":"10.1016\/j.canep.2025.102960_bib3","unstructured":"Myelodysplastic Syndromes Risk Factors, Cancer.org; 2024. Accessed 6 June 2025. \u3008https:\/\/www.cancer.org\/cancer\/types\/myelodysplastic-syndrome\/causes-risks-prevention\/risk-factors.html\u3009."},{"issue":"8","key":"10.1016\/j.canep.2025.102960_bib4","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.3390\/cancers13081968","article-title":"Myelodysplasia syndrome, clonal hematopoiesis and cardiovascular disease","volume":"13","author":"Veiga","year":"2021","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.canep.2025.102960_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24065734","article-title":"The genetic landscape of myelodysplastic neoplasm progression to acute myeloid leukemia","volume":"24","author":"B\u0103nescu","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.canep.2025.102960_bib6","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised International prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.canep.2025.102960_bib7","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular international prognostic scoring system for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid."},{"key":"10.1016\/j.canep.2025.102960_bib8","unstructured":"Key Statistics for Acute Myeloid Leukemia (AML), Cancer.org, 2025. Accessed 6 June 2025. \u3008https:\/\/www.cancer.org\/cancer\/types\/acute-myeloid-leukemia\/about\/key-statistics.html\u3009."},{"key":"10.1016\/j.canep.2025.102960_bib9","unstructured":"Acute Myeloid Leukemia - Cancer Stat Facts. SEER, 2018. Accessed 6 June 2025. \u3008https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html\u3009."},{"issue":"9","key":"10.1016\/j.canep.2025.102960_bib10","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1038\/s41375-023-01985-y","article-title":"Prognostic impact of secondary versus de novo ontogeny in acute myeloid leukemia is accounted for by the European LeukemiaNet 2022 risk classification","volume":"37","author":"Hochman","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.canep.2025.102960_bib11","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: recent progress and enduring challenges","volume":"36","author":"Shallis","year":"2019","journal-title":"Blood Rev."},{"key":"10.1016\/j.canep.2025.102960_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2025.01.012","article-title":"Characteristics and survival of secondary acute myeloid leukemia from myelodysplastic syndromes in older adults: a population analysis","author":"Batra","year":"2025","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.canep.2025.102960_bib13","unstructured":"Multiple Cause of Death Data on CDC WONDER, Cdc.gov, 2018. Accessed 6 June 2025. \u3008https:\/\/wonder.cdc.gov\/mcd.html\u3009."},{"key":"10.1016\/j.canep.2025.102960_bib14","unstructured":"United States Cancer Statistics Public Information Data, Cdc.gov, 2021. Accessed 6 June 2025. \u3008https:\/\/wonder.cdc.gov\/cancer.html\u3009."},{"key":"10.1016\/j.canep.2025.102960_bib15","unstructured":"Underlying Cause of Death 1999\u20132020, Cdc.gov, 2020. Accessed 6 June 2025. \u3008https:\/\/wonder.cdc.gov\/wonder\/help\/ucd.html\u3009."},{"key":"10.1016\/j.canep.2025.102960_bib16","unstructured":"Use of the 2000 U.S. Standard Population for Age-Adjustment \u2013 SEER Population Datasets, SEER, 2018. Accessed 6 June 2025. \u3008https:\/\/seer.cancer.gov\/stdpopulations\/2000stdpop-use.html\u3009."},{"key":"10.1016\/j.canep.2025.102960_bib17","unstructured":"Europe PMC, Europe PMC, Europepmc.org, 2016. Accessed 6 June 2025. \u3008https:\/\/europepmc.org\/article\/med\/22783637\u3009."},{"issue":"6","key":"10.1016\/j.canep.2025.102960_bib18","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s00277-016-2649-3","article-title":"Causes of death in 2877 patients with myelodysplastic syndromes","volume":"95","author":"Nachtkamp","year":"2016","journal-title":"Ann. Hematol."},{"issue":"9","key":"10.1016\/j.canep.2025.102960_bib19","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1002\/cncr.24984","article-title":"Cause of death in patients with lower-risk myelodysplastic syndrome","volume":"116","author":"Dayyani","year":"2010","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.canep.2025.102960_bib20","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/bjh.18542","article-title":"Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): a report from the European MDS registry","volume":"200","author":"M\u0105dry","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"10","key":"10.1016\/j.canep.2025.102960_bib21","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.3324\/haematol.2012.063420","article-title":"Infections in myelodysplastic syndromes","volume":"97","author":"Toma","year":"2012","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.canep.2025.102960_bib22","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.clml.2013.10.013","article-title":"Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis","volume":"14","author":"Jabbour","year":"2014","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"1","key":"10.1016\/j.canep.2025.102960_bib23","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1182\/blood.2019000942","article-title":"Genetics of progression from MDS to secondary leukemia","volume":"136","author":"Menssen","year":"2020","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.canep.2025.102960_bib24","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2016","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.canep.2025.102960_bib25","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.canep.2025.102960_bib26","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.canep.2025.102960_bib27","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.2005.05.4346","article-title":"Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the cancer and leukemia group B","volume":"24","author":"Silverman","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.canep.2025.102960_bib28","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.canep.2025.102960_bib29","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1038\/leu.2017.88","article-title":"Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised international prognostic scoring system","volume":"31","author":"Porta","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.canep.2025.102960_bib30","first-page":"1","article-title":"Acute myeloid leukemia in the older adults","volume":"6","author":"Almeida","year":"2016","journal-title":"Leuk. Res. Rep."},{"issue":"7","key":"10.1016\/j.canep.2025.102960_bib31","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.canep.2025.102960_bib32","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1016\/S2352-3026(19)30030-4","article-title":"An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study","volume":"6","author":"Savona","year":"2019","journal-title":"Lancet Haematol."},{"issue":"5","key":"10.1016\/j.canep.2025.102960_bib33","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with aFLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.canep.2025.102960_bib34","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.canep.2025.102960_bib35","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2008-01-134858","article-title":"Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001\u20132004, using data from the NAACCR and SEER programs","volume":"112","author":"Rollison","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.canep.2025.102960_bib36","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.hoc.2010.02.011","article-title":"The epidemiology of myelodysplastic syndromes","volume":"24","author":"Sekeres","year":"2010","journal-title":"Hematol.\/Oncol. Clin. N. Am."},{"issue":"14","key":"10.1016\/j.canep.2025.102960_bib37","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1182\/blood.2021012830","article-title":"Structural racism is a mediator of disparities in acute myeloid leukemia outcomes","volume":"139","author":"Abraham","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.canep.2025.102960_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2011\/107497","article-title":"Socioeconomic, rural-urban, and racial inequalities in US cancer mortality: Part I\u2014all cancers and lung cancer and Part II\u2014colorectal, prostate, breast, and cervical cancers","volume":"2011","author":"Singh","year":"2011","journal-title":"J. Cancer Epidemiol."},{"issue":"15","key":"10.1016\/j.canep.2025.102960_bib39","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1182\/blood-2011-12-399337","article-title":"Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes","volume":"119","author":"Thol","year":"2012","journal-title":"Blood"}],"container-title":["Cancer Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782125002206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782125002206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T07:35:53Z","timestamp":1780126553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877782125002206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":39,"alternative-id":["S1877782125002206"],"URL":"https:\/\/doi.org\/10.1016\/j.canep.2025.102960","relation":{},"ISSN":["1877-7821"],"issn-type":[{"value":"1877-7821","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Temporal trends in AML incidence and mortality, with a focus on AML-related deaths among patients with myelodysplastic syndromes in the United States, 1999\u20132023","name":"articletitle","label":"Article Title"},{"value":"Cancer Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canep.2025.102960","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102960"}}